The first drug developed independently by AbbVie for chronic HCV was approved in the United States. For the third year in a row, AbbVie achieved an excellent position in the Dow Jones Global Sustainability Index, which measures the performance of the world's largest companies based on long-term economic, environmental and social criteria and business practices that generate long-term shareholder value. After less than a year of existence, AbbVie ranked fourth on Science magazine's annual list of the best scientific employers, according to a survey of more than 3000 respondents. Working Mother magazine recognized AbbVie among the 100 best “Working Mother” companies for the third consecutive year.
However, Pfizer's profit percentage fell by 47%, Fortune said, which explains the drop in the ranking. Johnson & Johnson: In the latest Fortune rankings, life science giant J&J ranked 37th on the list of 500 companies. Bristol-Myers Squibb: At 138 on the Fortune 500 list, BMS rose seven spots from the previous year. This contribution, the largest single donation in the history of AbbVie and Ronald McDonald House Charities, provided essential support, such as housing, meals and education for hospitalized children and their families across the United States.
Zoetis: The last pharmaceutical company on the Fortune 500 list is Zoetis, an animal health company, based in New Jersey.